Amgen's $10B Onyx Deal Gets Antitrust Approval

Law360, New York (September 19, 2013, 2:04 PM EDT) -- Antitrust officials have approved Amgen Inc.'s $10.4 billion acquisition of Onyx Pharmaceutical Inc., the companies said Thursday, clearing the last regulatory hurdle and satisfying a major closing condition of the deal.

The waiting period under the Hart-Scott-Rodino antitrust law was set to expire next week, but the Federal Trade Commission cut their review short. Amgen and Onyx have few overlapping areas of research, and Onyx has just one proprietary drug on the market, so antitrust risk was seen to be low.

With approvals in hand, Amgen...
To view the full article, register now.